TGTX TG Therapeutics Inc

$36.70

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.

Website: https://www.tgtherapeutics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1001316
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, US
Valuation
Market Cap
$6.02B
P/E Ratio
255.47
PEG Ratio
0.00
Price to Book
27.07
Performance
EPS
$0.15
Dividend Yield
—
Profit Margin
7.11%
ROE
12.20%
Technicals
50D MA
$36.13
200D MA
$28.62
52W High
$43.32
52W Low
$12.93
Fundamentals
Shares Outstanding
157M
Target Price
$43.00
Beta
2.14

TGTX EPS Estimates vs Actual

● Estimated
● Actual

TGTX News & Sentiment

Sep 25, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Strength Seen in uniQure ( QURE ) : Can Its 247.7% Jump Turn into More Strength?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sep 24, 2025 • GlobeNewswire NEUTRAL
New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of patient treatment ...
Sep 10, 2025 • GlobeNewswire NEUTRAL
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. ( NASDAQ: TGTX ) , today announced the upcoming schedule of presentations highlighting BRIUMVI® ( ublituximab-xiiy ) data in patients with relapsing forms of multiple sclerosis ( RMS ) , at the 2025 European Committee for ...
Sep 08, 2025 • GlobeNewswire NEUTRAL
TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimens Phase 3 trial to evaluate two subcutaneous BRIUMVI dosing regimens ...
Sep 04, 2025 • Benzinga SOMEWHAT-BULLISH
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - TG Therapeutics ( NASDAQ:TGTX )
NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- TG Therapeutics, Inc. TGTX today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, being held in New York, NY on September 8 - 10, ...
Sep 04, 2025 • GlobeNewswire SOMEWHAT-BULLISH
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET Fireside chat scheduled for Monday, September 8, 2025, at 10:30am ET ...
Sentiment Snapshot

Average Sentiment Score:

0.272
50 articles with scored sentiment

Overall Sentiment:

Bullish

TGTX Reported Earnings

Apr 29, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Feb 26, 2025
Dec 31, 2024 (Pre market)
0.06 Surprise
  • Reported EPS: $0.15
  • Estimate: $0.09
  • Whisper: —
  • Surprise %: 66.7%
Nov 04, 2024
Sep 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.02
  • Estimate: $0.03
  • Whisper: —
  • Surprise %: -33.3%
Aug 06, 2024
Jun 30, 2024 (Pre market)
0.09 Surprise
  • Reported EPS: $0.04
  • Estimate: $-0.05
  • Whisper: —
  • Surprise %: 180.0%
May 01, 2024
Mar 31, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.07
  • Estimate: $-0.04
  • Whisper: —
  • Surprise %: -75.0%
Feb 28, 2024
Dec 31, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.10
  • Estimate: $-0.10
  • Whisper: —
  • Surprise %: 0.0%
Nov 01, 2023
Sep 30, 2023 (Pre market)
0.61 Surprise
  • Reported EPS: $0.73
  • Estimate: $0.12
  • Whisper: —
  • Surprise %: 508.3%
Aug 01, 2023
Jun 30, 2023 (Pre market)
-0.09 Surprise
  • Reported EPS: $-0.34
  • Estimate: $-0.25
  • Whisper: —
  • Surprise %: -36.0%
May 01, 2023
Mar 31, 2023 (Pre market)
0.09 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.37
  • Whisper: —
  • Surprise %: 24.3%

Financials